Dallas, TX – August 10, 2017 – Puration, Inc. (USOTC: PURA) today announced plans to enter the cannabis pharmaceutical market. The Company intends to focus first on a cannabis alternative to opioid pain killers. The focus on a cannabis alternative to opioid pain killers is driven by the prevailing opioid epidemic in the United States. A Whitehouse Commission has recently recommended that the opioid epidemic in the United States be declared a national emergency. Management plans to announce the Company’s detailed plans for entering the cannabis pharmaceutical market the first week in September.
The entry into the pharmaceutical market follows Puration’s recent acquisition of 25-greenhouse grow operation and signing of its first $1.2 million contract in conjunction with the acquisition and the Company’s plans to realize $100 million in potential annual sales from the acquisition.
Learn more about the acquisition and the Company’s growth plans:
Puration’s Grow Operation Business Strategy Overview
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Brian Shibley, CEO